The veterinary diagnostics market is projected to grow from USD 4.04 billion in 2022 to USD 7.27 billion by 2030, driven by the increasing prevalence of zoonotic diseases and the rising adoption of ...

Revvity, Inc. RVTY is well-positioned for growth in the coming quarters, thanks to its strong product portfolio. The optimism ...

Thermo Fisher Scientific Inc.’s TMO recent slew of strategic acquisitions reflects its ongoing commitment to sustainable long-term growth. End markets play an important role as well, bolstering Thermo ...

Looking ahead, DiaSorin anticipates continued growth into fiscal year 2025, guiding for 7% CER growth with an estimated €20 million in COVID revenues, which translates to roughly 8% growth excluding ...

The company’s growth strategy is supported by high single-digit growth in Immunodiagnostics, mid-teens growth in Molecular Diagnostics, and mid-single-digit growth in long-term targets.

Gary Falcetano, PA, is the U.S. Scientific Affairs Manager for Allergy in ImmunoDiagnostics at Thermo Fisher Scientific. A licensed physician assistant with more than 25 years of diverse ...

This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics ...

Ausria, a radioimmunoassay test to detect serum hepatitis, was launched in 1972 and marked the beginning of Abbott's immunodiagnostics business. A year later, the Abbott Diagnostics Division was ...

The firm said that a strong start to the commercialization of its Liaison Plex platform also aided growth in its molecular diagnostics business.

Understanding adaptive immunity is of paramount importance for the prevention and treatment of disease as well as the development of novel immunotherapeutics and immunodiagnostics (precision ...